Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-9-pyrido[1,2-a]pyrimidinyl]ethyl]amino]benzoic acid. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

9 träffar

Bibliografisk träff 2023-12-20

Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors.

Takarada JE, Cunha MR, Almeida VM, Vasconcelos SNS, Santiago AS, Godoi PH, Salmazo A, Ramos PZ, Fala AM, de Souza LR, Da Silva IEP, Bengtson MH, Massirer KB, Couñago RM.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117561

Bibliografisk träff 2021-08-12

Discovery and Toxicological Profiling of Aminopyridines as Orally Bioavailable Selective Inhibitors of PI3-Kinase γ.

Bellenie BR, Hall E, Bruce I, Spendiff M, Culshaw A, McDonald S, Ambarkhane A, Chinn C, Thomas M, Rosner E, Bracher M, Nicklin P, Marshall S, Coote J, Cullen E, Tessier C, Wuersch K, Lal A, Wallis G, Hollingworth GJ, Neef J.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.1c00986

Bibliografisk träff 2019-10-09

The Exploration of Chirality for Improved Druggability within the Human Kinome.

Saha D, Kharbanda A, Yan W, Lakkaniga NR, Frett B, Li HY.

J Med Chem · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.9b00640

Bibliografisk träff 2017-12-01

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368

Bibliografisk träff 2016-10-21

Class II Phosphoinositide 3-Kinases as Novel Drug Targets.

Falasca M, Hamilton JR, Selvadurai M, Sundaram K, Adamska A, Thompson PE.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.6b00963

Bibliografisk träff 2014-07-09

Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents.

Giordanetto F, Barlaam B, Berglund S, Edman K, Karlsson O, Lindberg J, Nylander S, Inghardt T.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2014.07.007

Bibliografisk träff 2014-06-21

Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.

Barlaam B, Cosulich S, Degorce S, Fitzek M, Giordanetto F, Green S, Inghardt T, Hennequin L, Hancox U, Lambert-van der Brempt C, Morgentin R, Pass S, Plé P, Saleh T, Ward L.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2014.06.040

Bibliografisk träff 2012-10-01

Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor.

Nylander S, Kull B, Björkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, Andersson M, Skärby T, Inghardt T, Fjellström O, Gustafsson D.

J Thromb Haemost · randomized controlled trial; journal article · DOI 10.1111/j.1538-7836.2012.04898.x

Bibliografisk träff 2012-09-06

Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.

Giordanetto F, Wållberg A, Ghosal S, Iliefski T, Cassel J, Yuan ZQ, von Wachenfeldt H, Andersen SM, Inghardt T, Tunek A, Nylander S.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2012.08.102